Shopping Cart 0
Cart Subtotal
USD 0

Arena Pharmaceuticals Inc (ARNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Arena Pharmaceuticals Inc (Arena) is a biopharmaceutical company which discovers, develops and commercializes small molecule drugs in multiple therapy areas. It is evaluating its lead candidate etrasimod for multiple inflammatory indications including ulcerative colitis, primary biliary cholangitis, pyoderma gangrenosum, and dermatologic extraintestinal manifestations of irritable bowel syndrome. The company is investigating ralinepag for the treatment of pulmonary arterial hypertension (PAH); and APD371 for pain associated with Crohn's disease. Arena is also developing Belviq (lorcaserin HCl) for chronic weight management for adults with obesity; nelotanserin for patients with Lewy body dementia (LBD) suffering from visual hallucinations. It has collaborations with Eisai, Axovant Sciences, Boehringer Ingelheim, and Beacon Discovery Inc. It has a manufacturing facility in Zofingen, Switzerland. Arena is headquartered in San Diego, California, the US.

Arena Pharmaceuticals Inc (ARNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Arena Pharma and Everest Medicines Enter into Agreement 12

Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 13

Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 14

Abic Marketing Enters into Agreement with Arena Pharma 15

Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 16

Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 18

Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 19

Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 20

Licensing Agreements 21

Outpost Medicine Enters into Licensing Agreement with Arena Pharma 21

Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 22

Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 24

Equity Offering 25

Arena Pharma Prices Public Offering of Shares for USD352.8 Million 25

Arena Pharma Raises USD172.5 Million in Public Offering of Shares 27

Arena Pharma Raises USD79.4 Million in Public Offering of Shares 29

Arena Pharma Raises USD3.2 Million in Public Offering of Shares 31

Arena Pharma to Raise Funds through Public Offering of Shares 32

Arena Pharma Completes Public Offering Of Common Stock For USD 70 Million 33

Arena Pharma Completes Private Placement Of Common Stock For USD 16.5 Million 34

Arena Pharma Completes Private Placement Of Series D Preferred Stock For USD 16.5 Million 36

Asset Transactions 38

Siegfried to Acquire Zofingen Manufacturing Facility from Arena Pharma 38

Arena Pharmaceuticals Inc-Key Competitors 39

Arena Pharmaceuticals Inc-Key Employees 40

Arena Pharmaceuticals Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Aug 06, 2018: Arena Pharmaceuticals provides corporate update and reports second quarter 2018 financial results 42

May 08, 2018: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results 44

Mar 14, 2018: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 45

Nov 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results 47

Aug 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results 48

May 09, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results 50

Mar 14, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 51

Corporate Communications 53

Jul 10, 2018: Arena Pharmaceuticals Names Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors 53

Feb 16, 2018: Arena Pharmaceuticals Announces Board Changes 54

Jun 14, 2017: Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors 55

Mar 20, 2017: Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer 56

Feb 14, 2017: Arena Pharmaceuticals Appoints Three New Members to Board of Directors 57

Product News 58

02/09/2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation-Inflammatory Bowel Diseases 2017 58

01/22/2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City 59

Clinical Trials 61

Oct 08, 2018: Arena Pharmaceuticals presented phase 2 clinical data for Etrasimod in ulcerative colitis at the American College of Gastroenterology Annual Meeting 61

Oct 02, 2018: Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension 62

Sep 24, 2018: Arena Pharmaceuticals reports positive phase 2a results for Olorinab in patients with abdominal pain associated with Crohn's disease 63

Sep 17, 2018: Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress 64

Aug 28, 2018: Arena Pharmaceuticals presented phase 1 clinical data for Ralinepag in pulmonary arterial hypertension at the European Society of Cardiology 65

May 21, 2018: Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference 66

Apr 12, 2018: Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting 67

Mar 19, 2018: Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis 68

Mar 01, 2018: Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn's Disease at American Pain Society Annual Scientific Summit 69

Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis 70

Oct 19, 2017: Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting 71

Sep 06, 2017: Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society 72

Aug 22, 2017: Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress 73

Jul 10, 2017: Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension 74

Jun 29, 2017: Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers 75

May 18, 2017: Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City 76

May 16, 2017: Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference 77

Apr 17, 2017: Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arena Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arena Pharma and Everest Medicines Enter into Agreement 12

Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 13

Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 14

Abic Marketing Enters into Agreement with Arena Pharma 15

Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 16

Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 18

Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 19

Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 20

Outpost Medicine Enters into Licensing Agreement with Arena Pharma 21

Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 22

Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 24

Arena Pharma Prices Public Offering of Shares for USD352.8 Million 25

Arena Pharma Raises USD172.5 Million in Public Offering of Shares 27

Arena Pharma Raises USD79.4 Million in Public Offering of Shares 29

Arena Pharma Raises USD3.2 Million in Public Offering of Shares 31

Arena Pharma to Raise Funds through Public Offering of Shares 32

Arena Pharma Completes Public Offering Of Common Stock For USD 70 Million 33

Arena Pharma Completes Private Placement Of Common Stock For USD 16.5 Million 34

Arena Pharma Completes Private Placement Of Series D Preferred Stock For USD 16.5 Million 36

Siegfried to Acquire Zofingen Manufacturing Facility from Arena Pharma 38

Arena Pharmaceuticals Inc, Key Competitors 39

Arena Pharmaceuticals Inc, Key Employees 40

Arena Pharmaceuticals Inc, Other Locations 41

Arena Pharmaceuticals Inc, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Arena Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Arena Pharmaceuticals Inc (Arena) is a biopharmaceutical company which discovers, develops and commercializes small molecule drugs in multiple therapy areas. It is evaluating its lead candidate etrasimod for multiple inflammatory indications including ulcerative colitis, primary biliary cholangitis, pyoderma gangrenosum, and dermatologic extraintestinal manifestations of irritable bowel syndrome. The company is investigating ralinepag for the treatment of pulmonary arterial hypertension (PAH); and APD371 for pain associated with Crohn's disease. Arena is also developing Belviq (lorcaserin HCl) for chronic weight management for adults with obesity; nelotanserin for patients with Lewy body dementia (LBD) suffering from visual hallucinations. It has collaborations with Eisai, Axovant Sciences, Boehringer Ingelheim, and Beacon Discovery Inc. It has a manufacturing facility in Zofingen, Switzerland. Arena is headquartered in San Diego, California, the US.

Arena Pharmaceuticals Inc (ARNA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Arena Pharma and Everest Medicines Enter into Agreement 12

Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 13

Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 14

Abic Marketing Enters into Agreement with Arena Pharma 15

Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 16

Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 18

Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 19

Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 20

Licensing Agreements 21

Outpost Medicine Enters into Licensing Agreement with Arena Pharma 21

Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 22

Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 24

Equity Offering 25

Arena Pharma Prices Public Offering of Shares for USD352.8 Million 25

Arena Pharma Raises USD172.5 Million in Public Offering of Shares 27

Arena Pharma Raises USD79.4 Million in Public Offering of Shares 29

Arena Pharma Raises USD3.2 Million in Public Offering of Shares 31

Arena Pharma to Raise Funds through Public Offering of Shares 32

Arena Pharma Completes Public Offering Of Common Stock For USD 70 Million 33

Arena Pharma Completes Private Placement Of Common Stock For USD 16.5 Million 34

Arena Pharma Completes Private Placement Of Series D Preferred Stock For USD 16.5 Million 36

Asset Transactions 38

Siegfried to Acquire Zofingen Manufacturing Facility from Arena Pharma 38

Arena Pharmaceuticals Inc-Key Competitors 39

Arena Pharmaceuticals Inc-Key Employees 40

Arena Pharmaceuticals Inc-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 42

Financial Announcements 42

Aug 06, 2018: Arena Pharmaceuticals provides corporate update and reports second quarter 2018 financial results 42

May 08, 2018: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results 44

Mar 14, 2018: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 45

Nov 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results 47

Aug 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results 48

May 09, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results 50

Mar 14, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 51

Corporate Communications 53

Jul 10, 2018: Arena Pharmaceuticals Names Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors 53

Feb 16, 2018: Arena Pharmaceuticals Announces Board Changes 54

Jun 14, 2017: Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors 55

Mar 20, 2017: Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer 56

Feb 14, 2017: Arena Pharmaceuticals Appoints Three New Members to Board of Directors 57

Product News 58

02/09/2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation-Inflammatory Bowel Diseases 2017 58

01/22/2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City 59

Clinical Trials 61

Oct 08, 2018: Arena Pharmaceuticals presented phase 2 clinical data for Etrasimod in ulcerative colitis at the American College of Gastroenterology Annual Meeting 61

Oct 02, 2018: Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension 62

Sep 24, 2018: Arena Pharmaceuticals reports positive phase 2a results for Olorinab in patients with abdominal pain associated with Crohn's disease 63

Sep 17, 2018: Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress 64

Aug 28, 2018: Arena Pharmaceuticals presented phase 1 clinical data for Ralinepag in pulmonary arterial hypertension at the European Society of Cardiology 65

May 21, 2018: Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference 66

Apr 12, 2018: Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting 67

Mar 19, 2018: Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis 68

Mar 01, 2018: Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn's Disease at American Pain Society Annual Scientific Summit 69

Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis 70

Oct 19, 2017: Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting 71

Sep 06, 2017: Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society 72

Aug 22, 2017: Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress 73

Jul 10, 2017: Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension 74

Jun 29, 2017: Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers 75

May 18, 2017: Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City 76

May 16, 2017: Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference 77

Apr 17, 2017: Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arena Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arena Pharma and Everest Medicines Enter into Agreement 12

Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 13

Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 14

Abic Marketing Enters into Agreement with Arena Pharma 15

Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 16

Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 18

Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 19

Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 20

Outpost Medicine Enters into Licensing Agreement with Arena Pharma 21

Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 22

Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 24

Arena Pharma Prices Public Offering of Shares for USD352.8 Million 25

Arena Pharma Raises USD172.5 Million in Public Offering of Shares 27

Arena Pharma Raises USD79.4 Million in Public Offering of Shares 29

Arena Pharma Raises USD3.2 Million in Public Offering of Shares 31

Arena Pharma to Raise Funds through Public Offering of Shares 32

Arena Pharma Completes Public Offering Of Common Stock For USD 70 Million 33

Arena Pharma Completes Private Placement Of Common Stock For USD 16.5 Million 34

Arena Pharma Completes Private Placement Of Series D Preferred Stock For USD 16.5 Million 36

Siegfried to Acquire Zofingen Manufacturing Facility from Arena Pharma 38

Arena Pharmaceuticals Inc, Key Competitors 39

Arena Pharmaceuticals Inc, Key Employees 40

Arena Pharmaceuticals Inc, Other Locations 41

Arena Pharmaceuticals Inc, Subsidiaries 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Arena Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.